by Furthermore, MSCs could also potentially modulate DC function through their effects on NK cell function (80,81). Much like MSCs, murine MAPCs have constitutive low-level expression of MHC class I that likely underlies their susceptibility to NK cell-mediated lysis (52). activation and function. Understanding this key obtaining may ultimately define the proper market for RSCT in allogeneic HSCT. In particular, mechanistic studies are needed to delineate thein vivoeffects of RSCT in response to inflammation and injury associated with allogeneic HSCT and to define the relevant sites of RSC conversation with immune cells in the transplant recipient. Furthermore, development ofin vivoimaging technology to correlate biodistribution patterns, desired RSC effect, and clinical end result will be crucial to establishing dose-response effects and minimal biologic-dose thresholds needed to advance translational treatment strategies for complications like GVHD. Keywords:Graft-versus-host disease, hematopoietic stem cell transplantation, immunomodulation, mesenchymal stem cell, microenvironment, multipotent adult progenitor cell, SPRY2 regenerative stromal cell therapy == Introduction == Culture adherent stem cells have been isolated from many adult and post-natal tissue sources, including bone marrow, cord blood, adipose and others. These stem cells share the common house of low immunogenicity and active immunomodulation, and depending on isolation and growth conditions, can participate in the regeneration of hurt tissue. The multipotent mesenchymal stem cell (MSC) is the most widely analyzed 17 alpha-propionate in both pre-clinical and clinical studies. We propose to classify these adherent stem cell cultures as regenerative stromal cells (RSCs), for the purpose of critiquing their role in tissue repair and immunomodulation in allogeneic hematopoietic stem cell transplantation. Allogeneic hematopoietic stem cell transplantation (HSCT) results in graft-versus-tumor (GVT) effects, which eliminate residual malignant cells via immunologic mechanisms. However, beneficial GVT activity shares similar immune pathways with deleterious acute graft-versus-host disease (GVHD). Therefore, separating these disparate immune responses within the allogeneic HSCT recipient remains a major challenge (1). Consequently, GVHD and malignant relapse are main causes of death following allogeneic HSCT (2). Current immunosuppressive therapy used to prevent and/or treat GVHD is usually suboptimal and can be detrimental by promoting infectious sequelae and relapse of malignant disease (2,3). Regenerative stromal cell therapy (RSCT) offers the unique potential to facilitate hematopoiesis and engraftment, to modulate alloimmunity without compromising GVT effects, and to promote immune reconstitution and tissue repair (4). In this regard, RSCT is emerging as a novel form of therapy for acute GVHD. This review will examine the immunobiology of RSCT as it relates to the pathophysiology of acute GVHD and focus on the role that relevant inflammatory microenvironments have on RSC activation and function. == Acute graft-versus-host disease == The underlying pathophysiology of acute GVHD entails donor T-cell activation by host alloantigens and secretion of donor-derived cytotoxic cytokines that impact host tissues (57). The resultant cytokine storm not only targets endothelium primarily within gut, liver and skin (8), but also damages the thymus (9) and lungs (10) of the transplant recipient. Endothelial cell (EC) injury is caused by both the conditioning regimen and the cytotoxic T-cells induced by acute GVHD (11). Whether EC activation is usually a consequence of antigen presentation by ECs themselves or by immune effector cells via cross-presentation is usually controversial (12). Yet hurt endothelium is usually a significant source of chemokines and growth factors, which recruit additional immune cells to sites of injury thereby propagating tissue damage in the host. Murine models of allogeneic HSCT have been instrumental in defining the immune responses underlying acute GVHD (13). Specifically, mouse models have recognized cellular and soluble factors that mediate and regulate the GVHD response. Consequently, these mediators have become targets for second-line therapies used to treat steroid-resistant acute GVHD (1416). However, immunomodulatory therapy is 17 alpha-propionate usually often suboptimal in treating acute GVHD and can increase the risk for opportunistic infections (17) and potentially disease relapse (18). Therefore, novel strategies are needed to reduce GVHD, to preserve GVT effects, and to facilitate engraftment and immune reconstitution. == Potential functions for regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplant == In addition to hematopoietic progenitor cells, the bone marrow microenvironment contains non-hematopoietic progenitor cells that give rise to the stroma of the bone marrow and have the potential to differentiate into cells from other connective tissue lineages such as bone, cartilage and excess 17 alpha-propionate fat. Such stromal cells are not a homogeneous populace of cells and have different regenerative potential (19,20). This review will focus on.
